Soolantra

Soolantra 1% Cream is a medicine used in the treatment of rosacea, which is an inflammatory condition that affects face. It helps in reducing the redness, swelling and pimples associated with rosacea.

Product dosage: 30 g
Package (num)	Per tube	Price	Buy
8	9.95 $	79.56 $ (0%)	🛒 Add to cart
10	8.42 $ Best per tube	99.45 $ 84.24 $ (15%)	🛒 Add to cart
Synonyms Ivrea

Soolantra (ivermectin) Cream, 1% is a prescription-only topical medication specifically formulated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adult patients. Its mechanism of action is distinct, targeting the inflammatory and potential parasitic components of this chronic cutaneous condition. This cream offers a well-tolerated, once-daily treatment option that integrates seamlessly into a dermatological management plan, aiming to reduce lesion count and improve overall skin appearance.

Features

• Contains 1% ivermectin as the active pharmaceutical ingredient.
• Formulated as a white to pale yellow hydrophilic cream.
• Delivered in a 30-gram or 45-gram aluminum tube.
• Designed for topical application only; not for oral, ophthalmic, or intravaginal use.
• Utilizes a non-comedogenic, oil-free base to minimize pore clogging.
• Preservative system includes phenoxyethanol and ethylhexylglycerin.

Benefits

• Targets the Root Cause: Demonstrates both anti-inflammatory and potential anti-parasitic (anti-Demodex) activity, addressing two hypothesized pathophysiological pathways in rosacea.
• Reduces Visible Lesions: Clinically proven to significantly decrease the number of inflammatory papules and pustules associated with rosacea.
• Improves Skin Quality: Long-term use can lead to a reduction in erythema (redness) and an overall improvement in skin texture and tone.
• Convenient Dosing Regimen: Requires only a once-daily application, promoting adherence to the treatment plan.
• Favorable Safety Profile: Generally well-tolerated by most patients, with a low incidence of systemic absorption and related adverse effects.
• Integrated Care: Serves as a cornerstone therapy that can be used in conjunction with other dermatological treatments as directed by a healthcare provider.

Common use

Soolantra is indicated exclusively for the topical treatment of inflammatory lesions of rosacea. Rosacea is a common chronic dermatosis primarily affecting the central face (cheeks, nose, chin, forehead), characterized by periods of exacerbation and remission. Its presentation includes transient or persistent central facial erythema, papules, pustules, telangiectasia, and in some cases, ocular involvement or phymatous changes. Soolantra is specifically targeted at the papulopustular subtype of the disease. It is not indicated for the treatment of other skin conditions such as acne vulgaris, perioral dermatitis, or seborrheic dermatitis, and a correct diagnosis by a qualified healthcare professional is essential before initiation of therapy.

Dosage and direction

For topical use only. Apply a thin layer of Soolantra Cream to the affected areas of the face once daily. Use a pea-sized amount for each area of the face (e.g., forehead, chin, nose, each cheek), spreading it gently and evenly. The cream should be applied to the entire affected area, not solely to individual lesions. Avoid contact with the eyes, lips, and mucous membranes. Hands should be washed immediately after application. The treatment is intended for long-term use, and improvement is typically observed after approximately 4 weeks of use, with continued improvement through week 12. Use exactly as prescribed by a physician; do not exceed the recommended dosage or frequency of application.

Precautions

• For External Use Only: Soolantra is not for oral, ophthalmic, or intravaginal use. If contact with the eyes occurs, rinse thoroughly with water.
• Irritation: If severe skin irritation or hypersensitivity occurs, discontinue use and consult a physician.
• Sun Exposure: While the vehicle is not known to be phototoxic, patients with rosacea are generally advised to use sun protection measures. A broad-spectrum sunscreen and protective clothing are recommended.
• Underlying Conditions: Use with caution in patients with known extremely severe or complicated forms of rosacea, or those with compromised skin barrier function (e.g., severe eczema, burns).
• Pregnancy and Lactation: Although topical application results in minimal systemic exposure, use during pregnancy or while breastfeeding should only be undertaken if the potential benefit justifies the potential risk to the fetus or infant. Consult a physician.

Contraindications

Soolantra Cream is contraindicated in individuals with a known hypersensitivity to ivermectin, any other ingredients in the formulation (e.g., carbomer copolymer type B, cetyl alcohol, oleyl alcohol, dimethyl isosorbide, glycerol monostearate, medium-chain triglycerides, polyoxyl 20 cetostearyl ether, propylene glycol, sodium hydroxide, sodium citrate dihydrate, citric acid monohydrate, phenoxyethanol, ethylhexylglycerin, and purified water), or to any other avermectins.

Possible side effect

The most common adverse reactions observed in clinical trials were skin-related and generally mild to moderate in severity. These include:

• Skin burning sensation
• Skin irritation
• Pruritus (itching)
• Dry skin
• Contact dermatitis Less commonly reported side effects include worsening of rosacea, erythema, and skin pain. Systemic adverse effects are rare due to low systemic absorption but are theoretically possible, especially if applied to a significantly compromised skin barrier or ingested.

Drug interaction

Formal drug interaction studies have not been conducted with topical ivermectin. However, due to minimal systemic absorption (~0.1% or less of the ivermectin dose) following topical application, the potential for pharmacokinetic drug interactions is considered very low. There are no known clinically significant interactions with systemically administered medications. As a standard precaution, patients should inform their physician of all medications they are using, including prescription, over-the-counter, and herbal products.

Missed dose

If a dose is missed, it should be applied as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Do not apply a double dose to make up for a missed one.

Overdose

Topical overdose is unlikely to lead to serious systemic effects due to limited absorption. Excessive application may increase the potential for the local adverse reactions described above (e.g., severe skin irritation). If the product is accidentally ingested, systemic effects similar to those seen with oral ivermectin overdose may occur. Symptoms of oral overdose may include headache, dizziness, nausea, vomiting, diarrhea, urticaria, and pruritus. In case of accidental ingestion, seek medical attention or contact a Poison Control Center immediately.

Storage

Store Soolantra Cream at room temperature, between 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F). Do not freeze. Keep the tube tightly closed when not in use. Keep out of reach of children and pets. Do not use after the expiration date printed on the tube and carton.

Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.

Reviews

• “As a dermatologist, Soolantra has become a first-line therapy in my practice for papulopustular rosacea. The dual mechanism of action provides a rational approach, and the once-daily dosing supports excellent patient compliance. I observe consistent and significant reductions in inflammatory lesion counts and an overall calming of facial erythema in the majority of my patients.” – Dermatologist, 15 years of experience.
• “The clinical trial data for ivermectin 1% cream is robust, demonstrating not only high efficacy but also a sustained effect and a remarkably favorable tolerability profile. It fills an important niche in our rosacea treatment arsenal.” – Clinical Researcher, Pharmaceutical Development.
• “From a patient perspective, the convenience of a once-daily application and the non-greasy, cosmetically elegant base are significant advantages over some older topical therapies. It has improved the quality of life for many of my patients who struggled with the visible symptoms of rosacea.” – Nurse Practitioner, Dermatology Clinic.